BiotechTube
Tubulis Technologies

Tubulis Technologies

Munich, Germany· Est.
tubulis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $208.7M

Overview

Tubulis Technologies is a private, clinical-stage biotech developing next-generation antibody-drug conjugates (ADCs) through its proprietary technology platforms. The company has advanced two in-house programs into clinical trials for solid tumors and is building a broader pipeline. With a strong scientific foundation and leadership team, Tubulis aims to overcome traditional ADC limitations, such as stability and payload scope, to create more effective and durable cancer therapies.

Oncology

Technology Platform

Proprietary suite for ADC design including the Alco5 conjugation platform, focusing on generating stable, homogeneous ADCs with expanded payload scope and superior biophysical properties.

Funding History

4
Total raised:$208.7M
Series BUndisclosed
Series B$138M
Series A$60M
Seed$10.7M

Opportunities

The rapidly expanding global ADC market, estimated to reach tens of billions, offers a significant opportunity.
Tubulis's technology addresses key limitations of current ADCs (stability, payload scope), positioning it to create best-in-class therapies for high-need cancers and attract lucrative partnerships.

Risk Factors

Primary risks include clinical failure of lead assets, intense competition from large pharma and other biotechs in the ADC space, and dependence on raising capital in volatile markets to fund operations and expensive clinical trials.

Competitive Landscape

The ADC field is highly competitive, dominated by players like AstraZeneca, Pfizer, and AbbVie, and enriched with biotechs like ImmunoGen and Genmab. Tubulis competes by focusing on proprietary conjugation and matching technologies to improve ADC stability and expand usable payloads beyond industry standards.

More companies in Antibody-Drug Conjugates →More companies in Germany →